Mometasone/olopatadine

Drug Profile

Mometasone/olopatadine

Alternative Names: GSP 301-1 NS; GSP 301-2 NS; GSP-301; Olopatadine/mometasone

Latest Information Update: 05 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Anti-inflammatories; Antiallergics; Antihistamines; Dibenzoxepins; Glucocorticoids; Pregnadienediols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 29 Mar 2017 Positive efficacy and adverse events data from a phase III trial in Seasonal allergic rhinitis released by Glenmark Pharmaceuticals
  • 01 Jan 2017 Glenmark Pharmaceuticals completes a phase III trial in Seasonal allergic rhinitis (In adolescents, In adults) in USA (NCT02870205)
  • 10 Nov 2016 Pharmacokinetics and adverse events data from a phase I trial in Healthy subjects presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (AAAAI-2016) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top